Federal contract award
75F40120C00085
CHARACTERIZATION OF SEVERE CORONAVIRUS INFECTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN91 — OTHER MEDICAL - BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $9.4M |
| Current contract value | $9.4M |
| Potential contract value / ceiling | $9.4M |
| Start date | Sep 10, 2020 |
| Current end date | Sep 14, 2025 |
| Potential end date | Sep 14, 2025 |
| Latest award activity | Sep 9, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 9, 2025 | P00004 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO MARCH 14, 2026. |
| Apr 29, 2025 | P00003 | $0 | THIS IS A UNILATERAL ADMINISTRATIVE MODIFICATION. LINE ITEM 1 (BASE) PERIOD OF PERFORMANCE END DATE IS BEING CHANGED FROM 09/14/2023 TO 09/14/2025. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.